Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2025-04-23 00:00:00 ET · period of report 2025-04-21 · accession 0001415889-25-011243 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-23 | 2025-04-21 | JANX | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $30.00 | -3,334 | 82.1K | -4% | -$100.0K |
| D | 2025-04-23 | 2025-04-21 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $4.21 | +3,334 | 85.5K | +4% | +$14.0K |
| D | 2025-04-23 | 2025-04-21 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $0.00 | -3,334 | 90.7K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-21 | S | D | 3,334 | $30.00 | 82,139 | D | — | — | |
| 2 | Common | Common Stock | 2025-04-21 | M | A | 3,334 | $4.21 | 85,473 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-04-21 | M | D | 3,334 | $0.00 | 90,665 | D | $4.21 · — to 2031-03-09 | 3,334 Common Stock | (F2) Immediately exercisable. |